StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ABBVBullishIndustry Newsnews
High materiality9/10

AbbVie Highlights AFFIRM Crohn's SKYRIZI Data and RINVOQ Real-World Evidence at ACG 2026

Oct 11, 2026, 2:31 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The combination of AFFIRM efficacy signals, long-term durability data, real-world RINVOQ outcomes, and an FDA submission for SKYRIZI induction in Crohn's creates multiple near-term catalysts that could lift ABBV's IBD franchise expectations and potentially support multiple expansion scenarios.

AI summary

What happened, with direct paths to the underlying reporting

AbbVie presented 22 abstracts at ACG 2026, highlighting AFFIRM's SKYRIZI efficacy in Crohn's disease and long-term endoscopic outcomes from FORTIFY and SEQUENCE. Real-world RINVOQ data in advanced Crohn's disease support its role for difficult-to-treat patients. The company also cited an FDA submission for SKYRIZI induction in Crohn's, signaling potential regulatory catalysts and upside for the IBD franchise.

  • AFFIRM Phase 3: SKYRIZI improved Crohn's remission vs placebo.
  • Endoscopic response higher; benefits persisted through Week 24.
  • FORTIFY shows 144-week open-label durability in complex CD.
  • 74.5% with fistulizing CD achieved no draining fistulas after 5 years.
  • ACG 2026 abstracts and FDA Crohn's induction submission signal catalysts.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event